Summary
Guardant Health, Inc. reported a total revenue of $128.7 million for the first quarter of 2023, a significant increase of 34% compared to the same period in 2022. This growth was primarily driven by the precision oncology testing segment, which saw a 35% increase in revenue, fueled by higher test volumes from both clinical customers and biopharmaceutical partners. Despite the robust revenue growth, the company continued to incur substantial operating losses, with a net loss of $133.5 million for the quarter, an increase from the $123.2 million net loss in the prior year. This widening loss is attributable to increased costs in cost of revenue and operating expenses, particularly in research and development and sales and marketing, as the company invests in product development and market expansion. As of March 31, 2023, Guardant Health maintained a strong liquidity position with approximately $937.0 million in cash, cash equivalents, and marketable debt securities, which the company believes is sufficient to fund operations for more than 12 months.
Financial Highlights
50 data points| Revenue | $128.71M |
| R&D Expenses | $93.13M |
| Operating Expenses | $262.77M |
| Operating Income | -$134.06M |
| Interest Expense | $644K |
| Net Income | -$133.53M |
| EPS (Basic) | $-1.30 |
| EPS (Diluted) | $-1.30 |
| Shares Outstanding (Basic) | 102.66M |
| Shares Outstanding (Diluted) | 102.66M |
Key Highlights
- 1Total revenue increased by 34% year-over-year to $128.7 million, driven by strong performance in precision oncology testing.
- 2Precision oncology testing revenue grew by 35% to $113.4 million, primarily due to increased test volumes from clinical and biopharmaceutical customers.
- 3Net loss widened to $133.5 million from $123.2 million in the prior year's quarter, reflecting increased operating expenses.
- 4Research and development expenses increased by 14% to $93.1 million, indicating continued investment in innovation and clinical studies.
- 5Sales and marketing expenses rose by 18% to $76.1 million, supporting commercial infrastructure and marketing initiatives.
- 6The company ended the quarter with a healthy cash and marketable securities balance of $937.0 million, providing a runway for future operations.
- 7Significant progress reported in the development of the Shield LDT test for colorectal cancer screening, including meeting co-primary endpoints in the ECLIPSE study and submitting a premarket approval application to the FDA.